LFCR (Lifecore Biomedical Inc.) יחס שווי שוק לשווי בספרים
Global supply chain stability from Asia and patent disputes are critically impacting the clinical testing sector. Lifecore Biomedical (LFCR) mitigates these risks by occupying a narrow niche in the production of complex sterile injectables, which shields the company from dumping. The market trend for the company's valuation, where the indicator stands at -7.09, is based on the work of elite biochemists and rigorous quality control within the CDMO sphere.
%3A%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%91%D7%99%D7%97%D7%A1%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvq8bmkb.8d-7aozthc&start=20220704&end=20261027&filename=GURU_Markets_-_LFCR_-_Lifecore-Biomedical_-_Market-Capitalization-to-Net-Assets "LFCR יחס שווי שוק לערך בספרים Lifecore Biomedical, Inc. (28.04.2023 - 27.10.2026) | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור Lifecore Biomedical (LFCR)
This indicator compares the market value of Lifecore Biomedical (LFCR) to its net assets, determining the investor premium over real capital amid interest rate volatility. Cost optimization through infrastructure outsourcing impacts the balance sheet structure, which is reflected in the multiple of market cap to book capitalization, helping to identify safe entry zones and risks of capital stagnation.